Enanta Pharmaceuticals (ENTA) Accumulated Depreciation & Amortization (2016 - 2025)
Enanta Pharmaceuticals' Accumulated Depreciation & Amortization history spans 14 years, with the latest figure at $23.8 million for Q3 2025.
- For Q3 2025, Accumulated Depreciation & Amortization fell 4.96% year-over-year to $23.8 million; the TTM value through Sep 2025 reached $23.8 million, down 4.96%, while the annual FY2025 figure was $23.8 million, 4.96% down from the prior year.
- Accumulated Depreciation & Amortization reached $23.8 million in Q3 2025 per ENTA's latest filing, up from $22.5 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $25.2 million in Q2 2024 to a low of $18.9 million in Q3 2021.
- Average Accumulated Depreciation & Amortization over 5 years is $22.5 million, with a median of $22.5 million recorded in 2025.
- Peak YoY movement for Accumulated Depreciation & Amortization: rose 20.75% in 2021, then decreased 10.67% in 2025.
- A 5-year view of Accumulated Depreciation & Amortization shows it stood at $18.9 million in 2021, then grew by 15.49% to $21.9 million in 2022, then rose by 8.63% to $23.7 million in 2023, then dropped by 15.23% to $20.1 million in 2024, then increased by 18.26% to $23.8 million in 2025.
- Per Business Quant, the three most recent readings for ENTA's Accumulated Depreciation & Amortization are $23.8 million (Q3 2025), $22.5 million (Q2 2025), and $21.3 million (Q1 2025).